Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)

French Society for Intensive Care

Status

Enrolling

Conditions

Ventilator Associated Pneumonia

Treatments

Drug: Antibiotic

Study type

Observational

Funder types

Other

Identifiers

NCT06243094

2023-A01492-43

Details and patient eligibility

About

The French Society of Intensive Care conducts a comprehensive assessment of current antibiotic therapy practices in critically ill patients suspected of Ventilator-Associated Pneumonia (VAP).

Full description

This prospective observational multicenter study will be conducted in intensive care units (ICU) across France and French-speaking regions. The primary objective of this study is to delineate the characteristics of antibiotic treatments administered for a first episode of suspected VAP. Secondary objectives include describing the outcomes of enrolled patients, assessing adherence to European guidelines regarding empirical antibiotic treatment, and identifying factors associated with mortality in patients with microbiologically confirmed VAP.

Enrollment

1,060 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Admission to the ICU
Intubation and duration of invasive mechanical ventilation > 48 hours
Initiation of new antibiotic therapy to treat a first suspicion of Ventilator-Associated Pneumonia (VAP)

Exclusion criteria

Presence of a decision to limit active therapeutic measures at the time of initiating antibiotic therapy
Organ donor
Prior inclusion in the study during a previous stay in the intensive care unit (a patient cannot be included multiple times)
Participation in an interventional study focusing on the management of VAP and directly impacting antibiotic therapy practices
Patient and/or family opposition to participation
Lack of affiliation with a social security system